Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-10-11 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchase transactions with dates, quantities, and prices, as well as confirmations regarding compliance with listing rules. The document references the Main Board Listing Rules and GEM Listing Rules of the Stock Exchange of Hong Kong. The content is focused on reporting share repurchases and changes in issued shares, which aligns with announcements of transactions in own shares. The document is substantive and detailed, not merely an announcement of a report or a certification. Therefore, it fits the category of 'Transaction in Own Shares' (POS).
2023-10-11 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSTER PRESENTATION OF PHASE II STUDY TOPLINE RESULTS OF FASN INHIBITOR ASC40 FOR TREATMENT OF ACNE AT EADV CONGRESS 2023
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the poster presentation of Phase II study topline results of a drug (ASC40) at a scientific congress (EADV Congress 2023). It contains detailed clinical trial results and study design but does not present comprehensive financial data, regulatory filings, or corporate governance information. It is not an annual or interim financial report, audit report, earnings release, or any other financial filing. The document is an announcement of clinical trial results presented at a conference, which is a business development update rather than a financial or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-10-11 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations that these repurchases comply with listing rules of the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases and changes in issued shares, not a financial report or earnings release. It is a formal notification of transactions in the company's own shares (share buybacks). Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is sufficient and contains detailed transactional data, confirming it is not a mere announcement or certification but a substantive report of share repurchase activity.
2023-10-10 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares on various dates, confirming compliance with listing rules of the Stock Exchange of Hong Kong (SEHK). The content focuses on share repurchase transactions, quantities, prices, and confirmations by the company secretary. There are no financial statements, earnings data, or management discussion. The document is a regulatory disclosure about share repurchases, which fits the definition of a 'Transaction in Own Shares' filing rather than a full financial report or announcement of voting results. Therefore, the appropriate classification is POS (Transaction in Own Shares). The document length and detail support a high confidence in this classification.
2023-10-09 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It references specific rules from the Stock Exchange of Hong Kong (SEHK) Listing Rules and details multiple repurchases of shares with dates and quantities. The content is a regulatory disclosure about share repurchases, including confirmations by the company secretary. There are no financial statements or management discussion, nor is it an announcement of a report publication. The document is a formal regulatory filing reporting share repurchase transactions and changes in issued share capital as required by the exchange rules. This fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2023-10-06 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It references specific rules from the Stock Exchange of Hong Kong (SEHK) Main Board Listing Rules and GEM Rules, indicating regulatory compliance disclosures. The content details repurchases of shares on various dates, quantities, prices, and confirmations by the company secretary. There are no financial statements or management discussion of financial results, nor is this an announcement of a report publication. The document is a regulatory disclosure about share repurchases and capital changes, fitting the category of Transaction in Own Shares (POS).
2023-10-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.